Background: Symptoms are known to predict survival among patients with heart failure (HF), but discrepancies exist between patients' and health providers' perceptions of HF symptom burden. Objective: The purpose of this study is to quantify the internal consistency, validity, and prognostic value of patient perception of a broad range of HF symptoms using an HF-specific physical symptom measure, the 18-item HF Somatic Perception Scale v. 3. Methods: Factor analysis of the HF Somatic Perception Scale was conducted in a convenience sample of 378 patients with chronic HF. Convergent validity was examined using the Physical Limitation subscale of the Kansas City Cardiomyopathy Questionnaire. Divergent validity was examined using the Self-care of HF Index self-care management score. One-year survival based on HF Somatic Perception Scale scores was quantified using Cox regression controlling for Seattle HF Model scores to account for clinical status, therapeutics, and lab values. Results: The sample was 63% male, 85% white, 67% functionally compromised (New York Heart Association class IIIYIV) with a mean (SD) age of 63 (12.8) years. Internal consistency of the HF Somatic Perception Scale was ! = .90. Convergent (r = j0.54, P G .0001) and divergent (r = 0.18, P > .05) validities were supported. Controlling for Seattle HF scores, HF Somatic Perception Scale was a significant predictor of 1-year survival, with those most symptomatic having worse survival (hazard ratio, 1.012; 95% confidence interval, 1.001Y1.024; P = .038). Conclusions: Perception of HF symptom burden as measured by the HF Somatic Perception Scale is a significant predictor of survival, contributing additional prognostic value over and above objective Seattle HF Risk Model scores. This analysis suggests that assessment of a broad range of HF symptoms, or those related to dyspnea or early and subtle symptoms, may be useful in evaluating therapeutic outcomes and predicting event-free survival.
S
ymptoms of heart failure (HF) drive care seeking and healthcare utilization and predict quality of life and survival. 1Y4 Costs associated with HF are estimated to be more than $30 billion annually, and approximately half of patients with HF die within 5 years of diagnosis. 5, 6 The high costs associated with HF are in part due to the need for repetitive hospitalization for treatment of escalating signs and symptoms of HF. 7 Patients with HF frequently experience multiple symptoms simultaneously, 8Y10 potentially increasing symptom burden, the cumulative sum, severity, and impact of symptoms on the individual. 9, 11 However, there is substantial variation in how signs and symptoms of HF are perceived and reported by patients. Assessment and documentation by clinicians also are variable. 12Y17 Therefore, methodically assessing patient perception of symptoms is of potential value for prediction of both morbidity and mortality risk in this population. Reliable and valid instruments to assess both the presence and burden/ interference associated with signs and symptoms of HF are needed to improve the ability to predict outcomes.
The effect of HF symptoms on survival has been investigated using measures that vary considerably in method and the number and type of symptoms assessed. 3,4,12,18Y20 For example, symptoms have been inferred from quality of life measures, 19 HF-specific symptom instruments, 3, 4, 20 study-specific questionnaires, 18 and symptom dairies. 12 Timeframes for symptom recall among the various measures range from 1 to 30 days, and the number of symptoms assessed ranges from a minimum of 4 up to 18. Finally, the type of signs and symptoms included in these measures vary considerably in scope. In particular, HF symptoms that are subtle in nature or early indicators of impending decompensation were limited in many measures used in studies on HF symptoms and survival. 4 ,12,18Y20 Moreover, the measurement of dyspnea, a hallmark symptom of HF that is well known to vary in intensity based on activity and illness severity, was limited to a single item in half of these studies 12, 18, 19 and dyspnea on exertion was measured in only 1 study. 3 Clearly, robust and sound measures are needed that assess the breadth and complexity of HF symptoms, including hallmarks and the early and subtle symptoms of impending decompensation. Therefore, the purpose of this study was to quantify the internal consistency, validity, and prognostic value of patient perception of a broad range of HF symptoms using an HF-specific physical symptom measure, the 18-item HF Somatic Perception Scale v. 3.
Method
A secondary analysis was conducted of 2 convenience samples with 18-item HF Somatic Perception Scale data: 1 that assessed symptoms prerandomization in a trial focused on symptom management 2 and 1 that evaluated symptoms among community-dwelling participants of 2 observational studies of HF symptoms. 3, 21 Sampling criteria were similar between the samples. Inclusion criteria included (a) a confirmed diagnosis of HF, (b) able to read and comprehend fifth grade English, (c) reachable by telephone, (d) absence of major cognitive impairment, and (e) willing and able to provide informed consent. Exclusion criteria included (a) major uncorrected hearing impairment, (b) major psychiatric illness (eg, schizophrenia), (c) major uncorrected visual impairment, (d) not expected to live for months, and (e) reversible HF (eg, HF due to high output states). Human subjects approval was secured from each of the principal investigator's institutions.
Measurement
Physical HF symptoms were measured using the HF Somatic Perception Scale v. 3, an 18-item Likert scale. The original scale 22 was expanded from 12 items to 18 to capture the more subtle symptoms of HF. Importantly, the development of the original HF Somatic Perception Scale and this current 18 item version was guided by the Lenz Theory of Unpleasant Symptoms, with respect to interactions among multiple symptoms, multiple influential pathophysiological mechanisms, situational factors, and performance (eg, health-related quality of life and clinical event risk). 23, 24 Additional items were added to assess dyspnea on exertion, fatigue, nocturia, and symptoms associated with right-sided congestion (ie, abdominal swelling and loss of appetite). 25 The HF Somatic Perception Scale asks participants how much they are bothered by symptoms in the past week using 5 response options ranging from 0 (I did not have the symptom) to 5 (extremely bothersome). Scores are summed, with higher values indicating higher symptom burden.
Convergent validity provides evidence of validity by examining the correlation between different measures of a construct. To support convergent validity, correlation of theoretically related construct measures should be high. 26, 27 The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item Likert scale health status measure that assesses physical function, symptoms, social function, self-efficacy, and quality of life among patients with HF. 28 The KCCQ is a reliable and valid measure of health status responsive to change clinical status. The 6-item Physical Limitation subscale of the KCCQ was used to examine convergent validity. Scores range from 1 to 36 on the Physical Limitation subscale. Higher scores indicate better function. The reliability of the Physical Limitation subscale is acceptable, with a Cronbach's ! of .90. We hypothesized that the correlation between the HF Somatic Perception Scale and KCCQ Physical Limitation subscale would be significant.
Discriminant validity examines differentiation of constructs that are theoretically different. To support discriminant validity, correlation between 2 different constructs should be low. 26, 27 The Self-care of HF Index (SCHFI) was used to quantify self-care. 29 The SCHFI v. 6.2 is a 22-item scale using a 4-point self-report response format to measure self-care maintenance (adherence behaviors), self-care management (response to symptoms), and self-care confidence. The 6-item Selfcare Management score was used to examine discriminant validity for this analysis because it reflects how quickly participants recognized and responded symptoms as opposed to the physical experience of symptoms. Symptom recognition options ranged from 0 (I did not recognize it as a symptom of HF) to 4 (very quickly). Response to symptom options included rating the likelihood of taking action to manage symptoms (eg, taking an extra diuretic, reducing fluid intake) from 1 (not likely) to 4 (very likely). Scores are standardized to range from 0 to 100, with higher values indicating better symptom response behaviors. The Self-care Management subscale of the SCHFI is multidimensional, with a 2-factor structure representing symptom evaluation and treatment implementation. Therefore, a global reliability index is used to assess internal consistency. The global reliability index derived from the weighted least squares means and variance is 0.77 and 0.76, respectively. 30 We hypothesized that the correlation between the HF Somatic Perception Scale and SCHFI Self-care Management subscale would be weak and insignificant. We completed a review of the electronic medical record at 1 year looking specifically for HF-related emergency department visits, hospitalizations, or mortality. For most events, data were extracted directly from discharge summaries of all participants who received care locally and were part of an extensively linked electronic medical record system. We also contacted study participants by telephone to inquire about events that occurred outside of the health system network; we solicited sufficient detail directly from participants or their family members to determine whether the event was primarily related to their HF or for other reasons. All events underwent adjudication by 2 separate evaluators until 100% agreement was reached about the underlying reasons for emergent healthcare utilization.
Analysis
The HF Somatic Perception Scale item response means and standard deviations and average interitem correlations (ie, the mean of all paired correlations between items) were quantified. 31 Item difficulty was assessed by quantifying the proportion of participants who provided the best possible response (I did not have this symptom). An item difficulty of 0.3 indicates that many (70%) participants had difficulty with the symptom, and an item difficulty of 0.7 indicates that few (30%) participants had difficulty with the symptom; between 0.3 and 0.7 is the best range for item difficulty. Item discrimination was quantified by comparing item difficulty between participants with HF Somatic Perception Scale total scores in the top and bottom thirds of the distribution.
Confirmatory factor analysis was performed using Mplus v. 6 (Los Angeles, California). Geomin (oblique) rotation was chosen for this analysis using weighted least square parameter estimation with mean-and varianceadjusted statistics. Results are presented in rotated factor loadings and standard errors. To assess model fit, overall model # 2 tests, comparative fit indices, TuckerLewis indices, root-mean-square errors of approximation, standardized root-mean-square residuals, normed fit index, and adjusted goodness-of-fit index were calculated using common thresholds of acceptability. 32 As the HF Somatic Perception Scale was developed as a unidimensional scale, Cronbach's ! was calculated as an index of internal consistency.
Pearson's correlations were used to quantify convergent (KCCQ Physical Limitations score) and discriminant validity (SCHFI Self-care Management). Finally, Cox proportional hazards modeling was performed using Stata MP v 13 (College Station, Texas) to quantify 1-year HF event risk (emergency department visit or hospitalization for HF or all-cause death) as a function of the HF Somatic Perception Scale scores. The proportional hazards assumption was justified based on Schoenfeld residuals. Hazard ratios (HR) and 95% confidence intervals are presented. To account for the influence of many other factors, the influence of symptom profiles on event-free survival was adjusted for the Seattle HF Score. The Seattle HF Score was calculated based on the original model developed by Levy and colleagues. 33 In brief, demographic (ie, age, gender) and objective clinical indices (ie, ischemic etiology, New York Heart Association functional class, left ventricular ejection fraction, systolic blood pressure, hemoglobin, percent lymphocytes count, uric acid, sodium, cholesterol) and HF treatment (ie, "-blocker, angiotensin converting enzyme inhibitor, allopurinol, diuretic dose, statin use, and device therapy) were multiplied by respective slope coefficients 33 to generate a single composite riskprediction score that in this sample ranged from j0.16 to 3.34.
Results
The samples used in this psychometric analysis are presented in Table 1 . In brief, the sample was predominantly male (63.2%), white (85.2%) older adults (mean age, 62.6 T 12.8 years). Most participants (67.2%) had New York Heart Association class III/IV symptoms.
Item Responses
Fatigue was the most commonly reported symptom (item difficulty, 0.09), and paroxysmal nocturnal dyspnea was the least commonly reported symptom (item difficulty, 0.66) ( Table 2 ). Average interitem correlations on the HF Somatic Perception Scale were consistent and ranged from 0.32 (It was hard for me to breath) to 0.35 (I had a cough), indicating that removing single items would not likely improve internal consistency. Most items were discriminatory regarding the top and bottom 33.3% of physical HF symptom burden. In contrast, having a cough, being tired, and waking up at night to urinate were not helpful in discriminating between participants who reported least versus most burdensome physical HF symptoms because they were either highly prevalent or were relatively normally distributed across response options.
Factor Analyses
The confirmatory factor analysis of the HF Somatic Perception Scale is presented in Table 3 . Several fit indices reached and others were close to reaching thresholds of acceptability; thus, the fit of the HF Somatic Perception Scale as a single scale could be improved. The best fit exploratory factor analysis of the HF Somatic Perception Scale, based on fit statistics and thresholds of acceptability, is also presented in Table 3 . The resulting subscales were labeled according to dominant features as ''dyspnea,'' ''chest discomfort,'' ''early and subtle,'' and ''edema.'' Considering these 4 factors, the fit of the HF Somatic Perception Scale was improved considerably.
Internal Consistency
The Cronbach's ! of the 18-item HF Somatic Perception Scale was .90. Single-item deletion did not result in significant improvement of internal consistency. Cronbach's ! was .89 on the 6-item dyspnea subscale. Cronbach's ! was .75 on the 7-item early and subtle subscale. Cronbach's ! was .75 and .68 on the edema and chest Measuring Patient Symptom Perception 143 discomfort subscales, respectively, but these scales contain too few items for meaningful analysis.
Convergent and Divergent Validity
Convergent validity testing of the HF Somatic Perception Scale with the KCCQ Physical Limitations score and discriminant validity testing of the HF Somatic Perception Scale with the SCHFI Self-care Management are presented in Table 4 . There were strong correlations between both the HF Somatic Perception
Scale and subscales and the KCCQ Physical Limitations score, indicating similarity between measures of theoretically related constructs. The HF Somatic Perception Scale and subscales were not correlated with SCHFI Self-care Management score, confirming discriminant validity. Convergent and discriminant validity testing was limited to the total HF Somatic Perception Scale and subscales for the dyspnea and early and subtle subscales because the chest discomfort and edema subscales had few items. 
Predictive Validity
The results of predictive validity testing are presented in Table 5 . The 18-item HF Somatic Perception Scale, 6-item dyspnea subscale, and 7-item early and subtle subscale were significantly associated with 1-year event risk when controlling for the Seattle HF Score. Survival curves depicting event-free survival differences across a gradient of physical symptoms by HF Somatic Perception Scale tertiles are presented in the Figure. The severe symptom tertile is associated with markedly increased risk of HF-related clinical risks compared with the low symptom tertile on the 18-item HF Somatic Perception Scale (HR, 1.65; P = .048), 6-item dyspnea subscale (HR, 1.70; P = .029), and 7-item early and subtle subscale (HR, 1.99; P = .010).
Discussion
The HF Somatic Perception Scale is a valid and reliable measure of HF symptom perception and burden in this sample of 378 adults with symptomatic HF. The HF Somatic Perception Scale total and dyspnea and early and subtle subscale scores were associated significantly with a measure of physical limitations and predicted HF event-free survival independent of a commonly used prognostication model. 33 Thus, the analysis indicates that patient perception of the physical symptoms of HF adds value when predicting clinical events.
The dyspnea subscale is a robust subscale, with good reliability and validity, that examines a broad range and severity of dyspnea symptoms related to HF. We found that the dyspnea subscale was effective in predicting HF-related clinical events. Clinical events were adjudicated for HF-specific events in this study. Conversely, dyspnea did not predict HF-related hospitalizations in the study by Ekman et al. 18 However, only 2 dyspnea symptoms were assessed and 1 (orthopnea) was assessed as present or absent. Similarly, dyspnea did not predict cardiac events in the study by Lee and colleagues. 19 A potential explanation for this is that dyspnea was limited to 1 item and clustered with fatigue and sleep disturbance in the survival analysis. The flexibility of using the HF Somatic Perception Scale dyspnea subscale is of interest for clinical and research use.
Importantly, assessment of the early and subtle symptoms of HF has clinical value. We found that increased severity of the early and subtle HF symptoms is associated with almost 2 times the risk of a clinical event within 1 year. Fatigue as a singular symptom (relative risk, 1.09; P = .018) 18 or clustered with other early and subtle symptoms (HR, 1.00; P = .011) 4 was a significant predictor of HF event risk in other studies. Accordingly, there are important implications of this finding for both patients and healthcare providers. First, patients often have difficulty recognizing and responding to escalation in burden of the subtle nonspecific symptoms of HF. 14, 34 Patients normalize and adjust to chronic symptoms, decreasing symptom interference on daily living.
14 However, lack of attention to early and subtle signs of decompensation may contribute to delay in self-management and or care seeking.
14 Patients with HF are typically instructed to monitor daily weights as an objective measure of increasing congestion. However, a disassociation between weight and dyspnea has been reported, potentially increasing the importance of assessing additional symptom parameters.
35Y37 Second, among patients with HF, cognitive impairment is common, can be subtle, and potentially impedes symptom reporting.
38Y40 Despite the prevalence of cognitive impairment in this population, it is infrequently documented in the medical record by healthcare providers. 41 Therefore, educating patients regarding the importance of monitoring the early and subtle symptoms of HF that are commonly attributed to less threatening illness is warranted. In addition, involving family and significant others in the education may improve effectiveness in detecting insidious increases in symptom severity. Taken together, evidence suggests that assessment of a broad range of HF symptoms may be useful in evaluating therapeutic outcomes, predicting survival, and informing clinical decision making.
Strengths and Limitations
There are several strengths and limitations to be considered in interpreting these results. Strengths of this analysis lie in the use of an HF-specific symptom scale and prospective documentation of symptom burden. Use of the HF Somatic Perception Scale also afforded assessment of a broad range of symptoms, including those potentially not reported by patients unless specifically asked. The survival analysis was strengthened by adjusting for clinical and treatment variables known to influence survival.
Limitations include a primarily male white sample, limiting the generalizability of the findings. In addition, the fit indices in this analysis were not perfect, but very good by most metrics. Although survival analyses are robust with smaller samples, additional testing of the predictive validity of the HF Somatic Perception Scale and subscales is needed. Future testing also is needed to examine differential item functioning by gender, race, ethnicity, and other factors.
h Patient perception of HF symptoms is an effective predictor of 1-year survival. h The HF Somatic Perception Scale Dyspnea subscale can be used alone to predict 1-year survival. It has validity and strong internal consistency. h Early and subtle symptoms of HF also have value in predicting 1-year survival.
